CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-25 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −1,010 | $16.02 | $16K | 168,562 |
| 2024-11-18 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −6,091 | $16.37 | $100K | 169,671 |
| 2024-11-18 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −99 | $17.05 | $2K | 169,572 |
| 2024-08-13 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Option exercise | +12,800 | $1.01 | $13K | 12,800 |
| 2024-08-13 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Option exercise · Stock Option (right to buy) | −12,800 | 161,394 | ||
| 2024-06-24 | Boyce Sarah Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2024-06-03 | Healy John Stephen General Counsel and Corp Sec | Grant or award · Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2024-05-24 | Stengone Carmine N. CEO and President | Grant or award · Stock Option (right to buy) | +285,000 | 285,000 | ||
| 2024-05-24 | Slover Peter T Chief Financial Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-05-24 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-05-24 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +3,700 | 3,700 | ||
| 2024-05-24 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-05-24 | Ignelzi Troy A. Director | Grant or award · Stock Option (right to buy) | +6,350 | 6,350 | ||
| 2024-05-24 | Ware Olivia C Director | Grant or award · Stock Option (right to buy) | +3,700 | 3,700 | ||
| 2024-05-24 | Lyons-Williams Lori Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2024-05-24 | Brady Todd R. Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2024-05-24 | Schimmelpennink Evert B. Director | Grant or award · Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2024-05-20 | Ignelzi Troy A. Director | Grant or award · Stock Option (right to buy) | +23,150 | 23,150 | ||
| 2024-04-09 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +391,785 | 391,785 | ||
| 2024-04-09 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +2,531 | 2,531 |
Page 6 of 7 · 139 trades